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Poster Session-I 81common signs of MS. 2 patients have developed overt diabetes and
are on insulin. Only 2 patients had history of GVHD treated with
steroids. No single factor could be associated with the risk of devel-
oping MS, though the number of cases is too small to do risk-factor
analysis. 2 patients also had GH deficiency. After diet modification
and exercise advise, 7 patients have been placed on Statins and except
for 1, all have tolerated it well with no liver dysfunction noted till
date (median treatment duration :12 months, range 3–23 months).
Conclusions: MS is highly prevalent in pediatric population post
-SCT. Both allogeneic and autologous SCT recipients are suscepti-
ble andMS is not restricted only to overweight recipients.MS should
be suspected, recognized and treated early, as it is a preventable cause
of cardio-vascular morbidity and mortality post-SCT.220
TACROLIMUS AND ‘‘MINI’’ METHOTREXATE IS AN EFFECTIVE REGIMEN
FOR PREVENTION OF GRAFT-VERSUS-HOST-DISEASE IN CHILDREN UN-
DERGOING UMBILICAL CORD BLOOD TRANSPLANT
Kelly, S.S.1, Kelly, P.2, Hunger, S.P.3, Wingard, J.R.2 1University of
Florida, Gainesville, FL; 2University of Florida, Gainesville, FL; 3The
University of Colorado Denver School of Medicine and The Children’s Hos-
pital, Aurora, CO
Historically, unrelated donor umbilical cord blood transplants
(UCBT) utilized corticosteroids and cyclosporine for graft-versus-
host disease (GVHD) prophylaxis. This combination is associated
with numerous complications including hyperglycemia, hyperten-
sion, avascular necrosis/osteoporosis, and significant infection risk.
Tacrolimus (FK506) and short-course methorexate (MTX) are
used widely for GVHD prophylaxis in adults undergoing hemato-
poietic stem cell transplant. Physicians have been reluctant to use ta-
crolimus/MTX for GVHD prophylaxis following UCBT due to
concerns over the potential for delayed engraftment and increased
mucositis. We report the University of Florida experience with the
combination of ‘‘mini’’ MTX and tacrolimus for GVHDprophylaxis
in children undergoing UCBT. Thirty-one children (ages four
months to 17 years) underwent UCBT between June 2004 and Sep-
tember 2007. Twenty-seven received cord blood from unrelated do-
nors and four from sibling donors. Units were matched with
transplant recipient at 6/6 (n 5 9), 5/6 (n5 11), or 4/6 (n5 11) hu-
man leukocyte antigen loci. Tacrolimus was started as a continuous
infusion at day -3, and changed to twice daily oral dosing when tol-
erated. All children were scheduled to receiveMTX 5mg/m2 on days
1, 3, 6 and 11 followed by lecovorin rescue. Tacrolimus was tapered
beginning between 100 and 180 days post transplant. Twenty-five of
29 eligible patients engrafted, with neutrophil engraftment (ANC.
500) occurring at a median of 18 (range 14–37) days post transplant.
Platelets were greater than 50,000/mm3 untransfused at a median of
42 days post transplant. Recovery of all cell lines occurred earlier
than in historical controls receiving cyclosporine and steroids.
Only one case of grade III or IV acute GVHDwas seen, and no cases
of extensive chronic GVHD. The severity of mucositis was very sim-
ilar to that observed with other GVHD prophylaxis regimens.
Transplant related mortality and infectious complications were as
expected or lower, with twenty children (65%) surviving event free
for a median of 24 (range 8- 45) months post transplant, (overall sur-
vival of 68%). Tacrolimus and ‘‘mini’’MTXwas a well-tolerated reg-
imen for GVHD prophylaxis in pediatric patients undergoing
UCBT. Engraftment kinetics, GVHD occurrence, survival and ad-
verse events compare favorably with historical data for other
GVHD prophylaxis regimens, making this an attractive option for
GVHD prophylaxis in pediatric UCBT.221
SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)— AN OPTION TO
CONSIDER
Duerst, R.E., Jacobsohn, D., Chaudhury, S., Schneiderman, J., Tse,W.T.,
Kletzel, M. Children’s Memorial Hospital and Feinberg School of Medi-
cine, Northwestern University, Chicago, IL
Relapse of ALL following allogeneic HSCT has had an extremely
poor prognosis. Although repeat allogeneic HSCT can be consid-ered, re-treatment with a second full intensity, myeloablative condi-
tioning (MAC) regimen results in significant non-relapse mortality
(NRM) as well as frequent relapse with\20% relapse-free-survival.
Our experience utilizing reduced intensity conditioning (RIC) for
repeat HSCT following prior MACHSCT or MACHSCT follow-
ing prior RIC HSCT for patients (pts) with ALL indicates repeat
HSCT can still lead to cure. We have treated 11 ALL pts with $2
allogeneic HSCT. Seven pts underwent RIC HSCT following at
least one prior MAC HSCT. Similarly, 4 pts who were first treated
with RIC HSCT subsequently underwent a MAC HSCT. The
RIC regimen was comprised of fludarabine, IV busulfan 2 days
and ATG. The MAC regimen was comprised of fTBI, etoposide
and cyclophosphamide. First HSCT donors were matched sibs for
8 pts. The donors for HSCT #2 were different for 8 pts whereas
the same matched sib donated twice for 3 pts. Ten of 11 used
PBSC forHSCT#2.Graft-versus-host disease (GVHD) prophylaxis
was cyclosporin A (CsA)6mycophenolate for RIC HSCT. GVHD
prophylaxis for the MAC #2 pts was tacrolimus-methotrexate-ATG
in 1, CsA alone in 1 and 2 pts received noGVHDprophylaxis. All pts
engrafted. Only one RICHSCT pt succumbed to NRM (pulmonary
failure, having received 2 prior HSCT, one with fTBI and a second
with 4 days of busulfan). Further relapse developed in 3 RIC pts, 2
have died of disease progression, the third pt is in CR, presently
off therapy. One of 4 pts undergoing MAC for HSCT #2 has re-
lapsed and is similarly, in CR, presently off therapy. Three EFS de-
veloped chronic GVHD, 3 did not. The disease-free interval
following HSCT #2 has exceeded that following HSCT #1 for 5
of 11 pts. Kaplan-Meier estimate of OS and EFS at 2-yrs are 72
and 50%, respectively.













HSCT #2RIC, n 5 7 5 M–2 F 8.9, (2-16) 19 (11-27) 5 (2-84) 30 (2.5-84)
MAC, n 5 4 2 M–2 F 13.4, (10-17) 15 (7-17) 20 (15-25) 22 (15-25)Our results suggest that despite relapse of ALL following an allo-
geneic HSCT, consideration should be given for a second allogeneic
HSCT with use of a different conditioning regimen.222
RELATIONSHIP BETWEEN DAY 0 CYCLOSPORINE LEVEL AND GRAFT-
VERSUS-HOST DISEASE IN PEDIATRIC HSCT
Duncan, C.N., Buonanno, M.R., Lehmann, L.E. Dana-Farber Cancer
Institute, Boston, MA
We investigated the relationship between the trough cyclosporine
(CSA) level on day 0 and the development of graft-versus-host dis-
ease (GVHD) in pediatric HSCT patients. We performed a retro-
spective review of 162 consecutive allogeneic patients who received
GVHD prophylaxis with CSA, corticosteroid, and short-course
methotrexate. We compared the incidence of acute GVHD
(aGVHD) at day 100 and chronic GHVD at 1-year post-HSCT in
patients with subtherapeutic and therapeutic CSA levels on day 0.
CSA was started on day -2 at a dose of 1.5 mg/kg every 12 hours.
Trough levels less than 125mcg/ml were considered subtherapeutic.
The underlying disease, age at transplant, sex, degree of HLA-
matching, and stem cell source were similar between patients with
therapeutic and subtherapeutic CSA levels. The mean CSA level
on day 0 was 98 mcg/ml (median 108.6) and 113 patients (69.8%)
had a subtherapeutic level. There was no significant difference be-
tween the mean CSA levels of patients that received unrelated donor
(114.7) and related donor (99.3) transplants. There was no significant
difference in the incidence of aGVHD or cGVHD between patients
with subtherapeutic (23%, 34.5%) and therapeutic (30.6%, 44.9%)
CSA levels on day 0 in patients that received unrelated donor or re-
lated donor transplants. All patients with subtherapeutic CSA levels
had dose adjustment and the mean CSA level on day 12 was 155.2
mcg/ml (median 146.5). The mean day at which a therapeutic CSA
level was reached for all patients was day 13.5. This institutional
82 Poster Session-Idata suggests that a CSA trough level less than 125 ng/ml on day 0 is
not predictive of acute or chronic GVHD.223
ASSESSMENT OF LUNG FUNCTION BEFORE AND AFTER ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION IN A SINGLE PEDIATRIC
CENTER
Quigg, T.C.1, Kim, Y.-J.3, Goebel, W.S.2, Spiegel, C.B.2, Haut, P.R.2
1Riley Hospital for Children-Indiana University School of Medicine, Indi-
anapolis, IN; 2Riley Hospital for Children-Indiana University School of
Medicine, Indianapolis, IN; 3Riley Hospital for Children-Indiana Univer-
sity School of Medicine, Indianapolis, IN
Background: Allogeneic hematopoietic stem cell transplantation
(aHSCT) is being used with increasing success in pediatric patients
to treat a variety of malignant and non-malignant diseases. However,
pulmonary complications account for meaningful morbidity and
mortality in aHSCT recipients.
Objective: We assessed the prevalence of pre and post-aHSCT
lung function abnormalities at Riley Hospital for Children to
identify risk factors that may predict post-aHSCT morbidity and
mortality.
Methods:We retrospectively reviewed the medical records of 46
patients, aged 5–21 years, who received aHSCT between 1 January
2001 and 31 December 2006. Forty-one patients, who underwent
pulmonary function tests (PFTs) both before and after aHSCT,
were eligible for analysis. Pertinent demographic, aHSCT and
treatment-related data, and baseline (pre-aHSCT), 1 and 2-year
post-aHSCT PFT data were collected. Forced expiratory volume
in 1 second (FEV1), forced vital capacity (FVC), residual volume
(RV), total lung capacity (TLC), and diffusion capacity for carbon
monoxide adjusted for alveolar volume and hemoglobin (DLCOa/
VA) were determined as percentage predicted for age, sex, and
length matched controls. Analyses included logistic regression,
with and without generalized estimating equations, and mixed
effects models.
Results: Significantly lower FEV1, FVC, TLC, but similar
FEV1/FVC was noted at 1 year post-aHSCT. However, these find-
ings were no longer significant at 2 years post-aHSCT. Low base-
line DLCOa/VA was associated with death. Refractory disease
before aHSCT was significantly associated with lower FEV1,
FVC, and TLC after aHSCT. Age, CMV status, previous pulmo-
nary-toxic chemotherapy, and aHSCT conditioning were not sig-
nificantly associated with outcomes. Acute and chronic graft
versus host disease (GVHD) was significantly associated with
higher post-aHSCT RV.
Conclusions: Obstructive lung patterns contribute to post-
aHSCT morbidity, especially in the first year following aHSCT.
Low baselineDLCOa/VAwas a risk factor formortality. Pediatric pa-
tients who have evidence of acute and chronic GVHD are more
likely to have associated obstructive lung disease which suggests
that therapeutic intervention may prevent morbidity. Further
prospective studies are needed to assess the utility of long-term respi-
ratory monitoring in pediatric aHSCT recipients.224
MATCHED UNRELATED BONE MARROW TRANSPLANT FOR OMENN SYN-
DROME
Nahum, A., Reid, B., Grunebaum, E., Roifman, C.M. The Hospital for
Sick Children
Little information is currently available on the outcome and the
long term restoration of immune function in infants with Omenn
syndrome (OS) treated with bone marrow transplantation (BMT).
We prospectively followed patients with OS who received matched
unrelated donor bone marrow transplantation at our center. En-
graftment, immune reconstitution and transplant-related complica-
tions were recorded. Humoral and cellular immunity were
evaluated. Six patients with OS were diagnosed at a mean age of
4.6 months. Two had mutations in the RMRP gene, one had mu-
tations in DNA Ligase 4, while the rest genotype could not be de-
termined. They received a matched unrelated donor bone marrowtransplantation as the first BMT at the mean age of 9.4 months. All
six patients are alive and well at a mean 95 months after transplant.
All patients have evidence of full hemopoetic engraftment and ro-
bust immune reconstitution. Three out of six patients developed
GvHD of Grade II or more, which was reversed in all patients
by using short courses of high dose methylprednisolone. We
have shown here that matched unrelated donor bone marrow trans-
plantation is highly effective in curing patients with Omenn syn-
drome regardless of their genotype. This mode of treatment
should be preferred for patients with OS when a related identical
donor is not available.225
RELATIONSHIP BETWEEN ACETAMINOPHEN DOSAGE AND DEVELOP-
MENT OF ORGAN DYSFUNCTION DURING PEDIATRIC HEMATOPOETIC
STEM CELL TRANSPLANT
McArthur, J.A.1, Mikhailov, T.1, Rothchild, C.1, Talano, J.A.2 1Medical
College ofWisconsin,Milwaukee,WI; 2Medical College ofWisconsin,Mil-
waukee, WI
Background: Patients undergoing chemotherapy and radiation
have been shown to be in a state of oxidative stress. Acetaminophen
is known to cause depletion of glutathione, a key component of the
body’s antioxidant defense mechanism. Acetaminophen is also
known to cause liver toxicity and recently has been linked with sever-
ity of lung disease in asthmatics and alcoholics. Therefore, we ques-
tioned whether acetaminophen usage in patients undergoing
hematopoetic stem cell transplant (HSCT) could place them at
risk for organ dysfunction.
Methods: A retrospective chart review was performed on all pa-
tients undergoing HSCT at the Children’s Hospital of Wisconsin
between January 1, 1995–January 1, 2005. Cumulative dosage of
acetaminophen in mg/ kg was calculated on all patients during con-
ditioning and the first 14 days after stem cell infusion. Charts were
reviewed for evidence of veno-occlusive disease (VOD) of the liver
as diagnosed by the attending HSCT physician, respiratory insuffi-
ciency as defined by requirement of $2 l/min of nasal cannula oxy-
gen, and renal insufficiency as defined by doubling of the serum
creatinine. Statistical analysis was done using the unpaired student
t-test.
Results: Preliminary analysis found 330 patients who underwent
HSCT during the study time period. There was a statistically signif-
icant difference in themean acetaminophen dose used in patient who
developed VOD (303 mg/kg) in comparison to those who did not
(213 mg/kg) with p5 .036. The difference in acetaminophen dosage
between those who developed renal insufficiency (278mg/kg) com-
pared to those who did not (210 mg/kg) was also significant (p 5
.028). The most significant difference was seen when comparing
patients who did (277mg/kg) and did not (202mg/kg) develop respi-
ratory insufficiency (p 5 .0019). Also of interest in our data set was
that of the 80 patients who developed respiratory insufficiency (re-
quirement of $2 l/min nasal cannula oxygen), 55 (69%) went on
to require some form of mechanical ventilation. The relative risk
of death in this population was 2.04 (95% CI 1.70–2.45).
Conclusion:This patient population is highly complex with mul-
tiple confounding variables. It is still unclear if acetaminophen is
a cause or marker of severity of illness in pediatric HSCT patients.
However, avoidance of frequent acetaminophen dosing may be ben-
eficial whenever possible.226
T-CELLS REDIRECTED AGAINST NKG2D-LIGANDS FOR THE IMMUNO-
THERAPY OF OSTEOSARCOMA
Kakarla, S.1,2, Shaffer, D.1,2, Ahmed, N.1,2, Wang, L.L.2, Lee, D.A.3,
Sentman, C.L.4, Gottschalk, S.1,2 1Baylor College of Medicine, Houston,
TX; 2Baylor College of Medicine, Houston, TX; 3University of Texas,
MDAnderson Cancer Center, Houston, TX; 4DartmouthMedical School,
Lebanon, NH
Background: Osteosarcoma is the most common pediatric bone
tumor. Despite aggressive multimodal therapy survival rates for pa-
tients with metastatic or recurrent disease remain poor. New
